Maintained strong cash position with approximately $325.0 million in cash and cash equivalents, expected to fund operations into 2028
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Sionna Therapeutics Advances Cystic Fibrosis Treatment with New Study
- Sionna Therapeutics Advances Phase 1 Study for Cystic Fibrosis Treatment
- Sionna Therapeutics announces initiation of PreciSION CF Phase 2a trial
- Sionna Therapeutics initiated with a Buy at Freedom Capital
- Sionna Therapeutics appoints Caroline Stark Beer as CBO